NASDAQ:RAPP Rapport Therapeutics (RAPP) Stock Price, News & Analysis $39.07 -0.32 (-0.81%) As of 09:57 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rapport Therapeutics Stock (NASDAQ:RAPP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rapport Therapeutics alerts:Sign Up Key Stats Today's Range$38.50▼$39.9050-Day Range$33.00▼$41.6752-Week Range$11.71▼$43.76Volume11,311 shsAverage Volume347,302 shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/APrice Target$57.86Consensus RatingModerate Buy Company Overview Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology. Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation. Its diverse pipeline includes antibody-based constructs and small-molecule inhibitors targeting both solid tumors and hematologic malignancies. Preclinical data have demonstrated promising anti-tumor activity and favorable safety profiles, supporting the advancement of several programs toward first-in-human studies. Headquartered in Massachusetts, Rapport Therapeutics collaborates with academic institutions, contract research organizations and industry partners to drive its research and development efforts. The company is led by a management team with extensive experience in oncology drug development, clinical operations and regulatory strategy. With a strategic focus on translating scientific insights into innovative cancer therapies, Rapport aims to improve outcomes for patients worldwide. AI Generated. May Contain Errors. Read More Rapport Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreRAPP MarketRank™: Rapport Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 339th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingRapport Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRapport Therapeutics has a consensus price target of $57.86, representing about 48.5% upside from its current price of $38.97.Amount of Analyst CoverageRapport Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rapport Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rapport Therapeutics are expected to decrease in the coming year, from ($3.25) to ($3.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rapport Therapeutics is -14.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rapport Therapeutics is -14.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRapport Therapeutics has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rapport Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.37% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 7.09.Change versus previous monthShort interest in Rapport Therapeutics has recently decreased by 8.69%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRapport Therapeutics does not currently pay a dividend.Dividend GrowthRapport Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rapport Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,908,941.00 in company stock.Percentage Held by Insiders12.48% of the stock of Rapport Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsRapport Therapeutics has minimal institutional ownership at this time.Read more about Rapport Therapeutics' insider trading history. Receive RAPP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RAPP Stock News HeadlinesIs Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?June 16, 2026 | insidermonkey.comRapport Therapeutics Holds 2026 Annual Shareholder MeetingJune 10, 2026 | tipranks.comBofA: Digital Dollar Coming 2025-2030Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix. A tax strategy quietly costing you thousands every year… Social Security timing that leaves real money on the table… An estate plan that's years out of date… An income strategy that could be working twice as hard… These aren't small details. For most, it can be the difference between a retirement that works… and one that slowly unravels. One conversation with the right person can surface exactly what's missing — and give you a clear picture of where you actually stand.July 6 at 1:00 AM | Money Pickle (Ad)Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comIs Rapport Therapeutics (RAPP) Using RAP-219 To Redefine Its Broader Neuroscience Investment Narrative?June 8, 2026 | finance.yahoo.comBTIG Raises its Price Target on Rapport Therapeutics (RAPP)June 6, 2026 | finance.yahoo.comRAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal EpilepsyJune 4, 2026 | tipranks.comRapport Therapeutics Inc RAPPMay 27, 2026 | morningstar.comMSee More Headlines RAPP Stock Analysis - Frequently Asked Questions How have RAPP shares performed this year? Rapport Therapeutics' stock was trading at $30.34 at the start of the year. Since then, RAPP shares have increased by 28.4% and is now trading at $38.97. How were Rapport Therapeutics' earnings last quarter? Rapport Therapeutics, Inc. (NASDAQ:RAPP) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.14. The company had revenue of $20 million for the quarter, compared to the consensus estimate of $7.50 million. When did Rapport Therapeutics IPO? Rapport Therapeutics (RAPP) raised $136 million in an initial public offering (IPO) on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share. How do I buy shares of Rapport Therapeutics? Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rapport Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Navios Maritime Partners (NMM). Company Calendar Last Earnings5/07/2026Today7/06/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 RAPP's financial health is in the Green zone, according to TradeSmith. RAPP has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RAPP Previous SymbolNASDAQ:RAPP CIK2012593 WebN/A Phone(857) 321-8020FaxN/AEmployeesN/AYear Founded2022Price Target and Rating Average Price Target for Rapport Therapeutics$57.86 High Price Target$80.00 Low Price Target$40.00 Potential Upside/Downside+48.5%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.48 million Net MarginsN/A Pretax Margin-536.39% Return on Equity-24.78% Return on Assets-23.44% Debt Debt-to-Equity RatioN/A Current Ratio27.08 Quick Ratio27.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.17 per share Price / Book3.83Miscellaneous Outstanding Shares47,830,000Free Float41,858,000Market Cap$1.86 billion OptionableN/A Beta0.94 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:RAPP) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersBofA: Digital Dollar Coming 2025-2030Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredHe’s Back. And He’s About to ActThe U.S. government holds 8,133 tonnes of gold valued at just $42.22 an ounce on its books - while gold trades...Priority Gold | SponsoredElon Musk on His New Invention: “An Infinite Money Glitch.”Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...Chaikin Analytics | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
